Ixiaro: Japanese encephalitis vaccine approved for paediatric use

Children aged 2 months and older can now receive the Japanese encephalitis vaccine, Ixiaro.

Japanese encephalitis is found in most countries in Asia and also in some remote parts of northeast Australia | SCIENCE PHOTO LIBRARY
Japanese encephalitis is found in most countries in Asia and also in some remote parts of northeast Australia | SCIENCE PHOTO LIBRARY

Dosage regimen

The dose for children aged between 2 months and 3 years is 0.25ml and for children aged 3 to 18 years is 0.5ml. The lower dose is administered using the existing 0.5ml prefilled syringe but healthcare professionals must discard the excess volume before injection, as directed in the product literature. For both age groups, the vaccine should be given as two doses 28 days apart. There are no data available on booster doses in the paediatric population.

Give by intramuscular injection

The vaccine should be injected intramuscularly into the deltoid muscle; however, the anterolateral aspect of the thigh may be used in infants. The subcutaneous route may be used in patients with bleeding disorders, although there are no clinical efficacy data to support administration by this route.

Efficacy supported by two key studies

Evidence supporting this licence extension comes from two key randomised, open-label studies investigating the immunogenicity and safety in children aged between 2 months and 18 years. The first study was conducted in the Philippines, a country where JEV is endemic, and the second is an ongoing, uncontrolled trial in non-endemic countries (the US, Europe and Australia) in subjects with planned travel to an endemic area.

In both studies, seroconversion rates, defined as JEV neutralising antibody titre ≥1:10, were at least 85% at month 7 following vaccination. The safety profile was comparable to that of Havrix or Prevenar.

View Ixiaro drug record

Further information: Novartis Vaccines

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.